Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Surgery‐ineligible elderly patients with cutaneous squamous cell carcinoma of the head and neck region gain clinical benefit from definitive weekly hypofractionated radiotherapy

Title: Surgery‐ineligible elderly patients with cutaneous squamous cell carcinoma of the head and neck region gain clinical benefit from definitive weekly hypofractionated radiotherapy
Authors: De Felice, Francesca; Serpone, Maria; Cattaneo, Carlo Guglielmo; Di Giammarco, Federico; Fallico, Alberto; Delle Donne, Alessia; Lanzilao, Maura; Vitti, Elisa; Marampon, Francesco; Musio, Daniela; Tombolini, Vincenzo; Minniti, Giuseppe
Contributors: De Felice, Francesca; Serpone, Maria; Cattaneo, Carlo Guglielmo; Di Giammarco, Federico; Fallico, Alberto; Delle Donne, Alessia; Lanzilao, Maura; Vitti, Elisa; Marampon, Francesco; Musio, Daniela; Tombolini, Vincenzo; Minniti, Giuseppe
Publisher Information: John Wiley and Sons Inc; 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
Publication Year: 2023
Collection: Sapienza Università di Roma: CINECA IRIS
Subject Terms: cutaneous squamous cell carcinoma; definitive RT; elderly; hypofractionated RT; unfit patients
Description: BackgroundTo evaluate the role of definitive weekly hypofractionated radiotherapy (RT) for the treatment of surgery-ineligible elderly patients with cutaneous squamous cell carcinoma of the head and neck region (cHNSCC). MethodsEligible elderly patients (aged & GE;75 years) with cHNSCC were included. Patients received definitive weekly hypofractionated RT, using megavoltage electrons, to a total dose of 56-64 Gy (8 Gy per fraction). Primary endpoint was objective response rate (ORR), defined as the percentage of patients with a complete (CR) or partial response (PR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), pain response, tolerability, and safety. ResultsA total of 19 patients with 27 lesions were included and treated with definitive weekly hypofractionated RT. All patients received the prescribed total dose. ORR was 92.6%, including 70.4% of lesions with a CR and 22.2% with a PR. Median DOR was 12 months. No severe toxicity occurred. ConclusionsOur study confirmed the satisfying efficacy and acceptable toxicity of definitive weekly hypofractionated RT for cHNSCC in elderly patients. Our results establish weekly hypofractionated scheduleas a promising treatment option for elderly patients with cHNSCC.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/37439379; info:eu-repo/semantics/altIdentifier/wos/WOS:001026884300001; volume:45; issue:9; firstpage:2363; lastpage:2368; numberofpages:6; journal:HEAD & NECK; https://hdl.handle.net/11573/1719059
DOI: 10.1002/hed.27454
Availability: https://hdl.handle.net/11573/1719059; https://doi.org/10.1002/hed.27454
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.9B4AD943
Database: BASE